Press Release
Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c
- Phase II trial will assess efficacy and tolerability of NX210c in
Amyotrophic Lateral Sclerosis (ALS) patients - 80 patients due to be enrolled with first results expected in early 2026
- NX210c drug candidate allows for promising approach to repairing
Blood Brain Barrier (BBB) which is impaired in neurodegenerative
diseases such as ALS
